

### REMARKS

As a result of the foregoing amendment, the specification has been corrected pursuant to the Examiner's instructions.

In addition, claims 10, 12 and 15 have been amended to recite the specific steps for raising the antibodies namely, injecting a laboratory animal and thereafter collecting the antiserum. This is in accordance with the original disclosure at page 14, in paragraph [46].


Accordingly, it is submitted that the objection to the claims with respect to the spelling of dichlorotyrosine as well as the rejection under the second paragraph 35 U.S.C. has been obviated in as much as the claims recite how the antigen is used to raise antibodies. Accordingly, the rejection under the second paragraph 35 U.S.C 112 should be withdrawn.

The Examiner's indication that the claims 6-9 are allowable and claims 10-12, and 14-15 would be allowable if rewritten to overcome the rejections under 35 U.S.C 112 is appreciatively acknowledged.

It is believed all of the requirements have now been accommodated and this application is in condition for allowance and favorable reconsideration and prompt Notice of Allowance are earnestly solicited.

Respectfully submitted,

Dated: December 28, 2007

  
\_\_\_\_\_  
Jules E. Goldberg (Reg. No. 24,408)  
Reed Smith LLP  
599 Lexington Avenue  
New York, NY 10022  
Tel. No. (212) 521-5403

Attorneys for Applicants